Forty-nine per cent of patient advocacy groups represent patient interests to regulators. Participation in HTA and reimbursement reviews is most common (23%), while fair medicine pricing is the leading advocacy priority (21%).
49% of respondents from Patient advocacy ‘Regularly’ or ‘Sometimes’ represent patient interests to drug regulators
Patient groups representing each Patient advocacy sub-type
91 patient groups across 5 sub-types
interactions
Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making.
National patient-advocacy group, Canada
interactions
We provided comments to federal and state regulators around drug pricing in the 340B program [in the US, these reforms seek to overhaul the 1992 federal program that mandates pharmaceutical manufacturers provide steep drug discounts to safety-net hospitals and clinics] when asking for community input to proposed policy changes.
We provided comments to federal and state regulators around drug pricing in the 340B program when asking for community input to proposed policy changes.
National patient-education group, USA
actions & advocacy
We comment on all draft proposals of health laws, we initiate the new health regulations, we are in majority of MoH's committees [in Slovakia].
We comment on all draft proposals of health laws. We initiate the new health regulations. We are in the majority of MoH’s committees.
National patient-advocacy group, Slovakia
actions & advocacy
We bring patient perspectives opposing use of QALYs [quality-adjusted life years] and opposing importing drug prices from other countries [outside of the USA], especially those that use QALYs.
National patient-advocacy group, USA
The percentages below highlight how the 39 patient groups interact with regulators and advocate for patient interests. As respondents may be represented in more than one area, percentages may not total 100%.
interactions
23 mentions
9 mentions
6 mentions
5 mentions
2 mentions
1 mention
8 mentions
7 mentions
1 mention
5 mentions
3 mentions
1 mention
1 mention
5 mentions
4 mentions
1 mention
2 mentions
2 mentions
actions & advocacy
12 mentions
8 mentions
2 mentions
1 mention
1 mention
9 mentions
7 mentions
1 mention
1 mention
4 mentions
3 mentions
1 mention
2 mentions
2 mentions
1 mention
1 mention
1 mention
1 mention
GET THE REPORT
Our research covers 2,262 patient groups representing 100 countries and 45 therapy areas. The sample report shows you the depth of analysis for a single country or therapy area. To access any other reports, please get in touch.
Visit patient-view.com to gather more information or email: Alex Wyke, alexwyke@patient-view.com
